COVID-19: Hydroxychloroquine-azithromycin mix dangerous for heart

Cardiologists from Oregon Health & Science University (OHSU) and Indiana University recommend clinicians who treat COVID-19 patients with the malaria-antibiotic drug combination to also consider monitoring those patients for "ventricular arrhythmia," which involves the lower heart chambers beating quickly and irregularly and can lead to cardiac arrest.

New York: As the combined use of anti-malaria drug hydroxychloroquine and the antibiotic azithromycin to treat coronavirus patients gains momentum, cardiologists are advising caution because both medications can increase the risk for dangerous abnormal heart rhythms.

In guidance published in the American College of Cardiology publication titled ‘Cardiology Magazine', cardiologists from Oregon Health & Science University (OHSU) and Indiana University recommend clinicians who treat COVID-19 patients with the malaria-antibiotic drug combination to also consider monitoring those patients for "ventricular arrhythmia," which involves the lower heart chambers beating quickly and irregularly and can lead to cardiac arrest.

There are hundreds of drugs that can increase the risk for cardiac arrest, but using two together in patients who are already at risk or critically ill could increase that risk further, the authors warned.

"While there is yet very little data regarding hydroxychloroquine and azithromycin's effectiveness as a treatment for COVID-19, some clinicians are considering combining them during this global pandemic," said lead author Eric Stecker, associate professor of medicine (cardiovascular medicine) in the OHSU School of Medicine and OHSU Knight Cardiovascular Institute.

"If physicians use their best medical judgement and order this drug combination for coronavirus patients, we want them to be aware of potential adverse side effects," he added.

Stecker and colleagues recommend clinicians who treat COVID-19 patients with the drug combination also monitor patients for dangerous arrhythmias.

However, they acknowledge limited resources could make monitoring a challenge.

"Until we have clinical outcome data supporting the benefit or harm of these medications, I would advocate for a cautious approach in using the combination of hydroxychloroquine and azithromycin," said Stecker.

Any medications that increase the risk of cardiac risk require consideration of both risks and benefits.

"Right now, we do not have evidence that benefits outweigh risks for use of hydroxychloroquine or chloroquine," the study said.

Patients should be monitored for arrhythmias during any use of these medications, alone or in combination unless the risk of infection for health care workers or limitations in the use of personal protective equipment is prohibitive," said the authors.

IANS